Hims & Hers Scales Technology-Enabled, Vertically Integrated Care
HIMS deepens its technology-enabled care model with new offerings in GLP-1 weight loss, hormone health, and custom treatments.
Hims & Hers: Fast-Fashion Healthcare Is The Future (Rating Upgrade)
We're turning bullish on Hims & Hers now that we believe the worst is priced in. Q3 results confirm that the growth story remains centered around personalized plans driving 50% Y/Y revenue growth. Hence, it see longer-term financial leverage from scaling that business model. The "active discussions" with Novo Nordisk are a cherry on top but we see green shoots outside of weight-loss drugs that'll support growth.
Hims & Hers Expands AI-Driven Personalized and Subscription-Based Care
HIMS expands its AI-powered, subscription-based care model globally, backed by $870 million in fresh funding for growth.
Is Most-Watched Stock Hims & Hers Health, Inc. (HIMS) Worth Betting on Now?
Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Hims & Hers Stock Slips Post Y/Y Q3 Earnings Decline, Margins Contract
HIMS reports lower third-quarter 2025 earnings even as revenue and subscriber growth remain strong across its channels.
Why Hims & Hers Stock May Be a Buy After Mixed Q3 Results
Hims & Hers Health Inc. NYSE: HIMS stock is holding onto a slight gain the day after the company delivered a mixed third-quarter earnings report. The caution centers around the company's valuation, which makes it an outlier among healthcare stocks.
Hims & Hers Health, Inc. (HIMS) Q3 Earnings Match Estimates
Hims & Hers Health, Inc. (HIMS) came out with quarterly earnings of $0.09 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.06 per share a year ago.
Hims & Hers Health, Inc. (HIMS) Q3 2025 Earnings Call Transcript
Hims & Hers Health, Inc. ( HIMS ) Q3 2025 Earnings Call November 3, 2025 5:00 PM EST Company Participants Bill Newby Andrew Dudum - Co-Founder, Chairman & CEO Yemi Okupe - Chief Financial Officer Conference Call Participants Justin Patterson - KeyBanc Capital Markets Inc., Research Division Maria Ripps - Canaccord Genuity Corp., Research Division Craig Hettenbach - Morgan Stanley, Research Division Brian Tanquilut - Jefferies LLC, Research Division Eric Percher - Nephron Research LLC Ryan MacDonald - Needham & Company, LLC, Research Division Jungwon Kim - TD Cowen, Research Division Presentation Operator Thank you for standing by. My name is Eric, and I will be your conference operator today.
Hims & Hers Scales AI-Driven Personalized Health and Wellness
HIMS scales AI-driven care with new hormonal health lines, global expansion plans and a $870 million funding boost.
Struggling Healthcare Stock Ripe For Bull Notes
Shares of Hims & Hers Health (HIMS) are headed for their fourth-straight daily drop, down 2.4% to trade at $45.53 at last check, as investors look ahead to the company's third quarter results, due out after the close Monday, Nov. 3. Since hitting a February record high of $72.98, the stock has staged several rallies that have run out of steam around $65.
Can Sustained Product Demand Drive HIMS Stock Before Q3 Earnings?
Hims & Hers benefits from strong platform engagement and hormonal health launches ahead of third-quarter 2025 earnings.
Hims & Hers Health, Inc. (HIMS) Stock Dips While Market Gains: Key Facts
Hims & Hers Health, Inc. (HIMS) reached $47.12 at the closing of the latest trading day, reflecting a -2.3% change compared to its last close.
